| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
At Mayo Clinic, we know the importance of laboratory testing in a patient’s episode of care. Our unique combination of specialized laboratories and cardiology patient care clinics allows us to reduce downstream costs with care-driven testing approaches that produce definitive diagnoses. Our testing can also identify at-risk patients who require earlier intervention or increased surveillance through the most advanced techniques and technologies developed and validated in clinical practice.
OUR DIFFERENCE
The latest
Short, interactive case studies from Mayo Clinic physicians, scientists, and allied health staff.
With more than 70,000 uses worldwide and policy endorsements for its use (JAMA Article), the Mayo Clinic Statin Choice Decision-Aid tool is helping patients and their clinicians have meaningful conversations about whether or not to use statins to reduce cardiovascular risk.
High-sensitivity cardiac troponin levels are strongly associated with the risk for incident heart failure. Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, weighs in on the topic.
This week’s Research Roundup highlights how cardiac troponin is released from injured myocardium.
Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, spoke with CAP Today about what a new higher-sensitivity cardiac troponin assay means from a pathology and cardiology perspective.
This week’s Research Roundup highlights global pulmonary vascular remodeling in pulmonary hypertension associated with heart failure and preserved or reduced ejection fraction.
Researchers from Mayo Clinic and the Johns Hopkins University School of Medicine published an article in "JAMA Internal Medicine" outlining the elimination from clinical practice of a popular test for diagnosing heart attacks.
Sudden cardiac death and episodes of fainting and seizures from long QT syndrome are significantly lower than previously thought when patients are diagnosed and treated at a specialty center dedicated to the treatment of genetic heart rhythm diseases, according to Mayo Clinic research published in the Journal of the American College of Cardiology.
European Heart Journal recently highlighted Mayo Clinic's new blood test that may predict cardiovascular events in patients with or without coronary artery disease.
Jeff Meeusen, Ph.D., a clinical chemist and Co-Director of Cardiovascular Laboratory Medicine at Mayo Clinic, discussed Mayo Clinic's new blood test that helps combat the leading cause of death in the U.S. on Voice of America.
A new type of blood test may help physicians identify which patients with and without evidence of coronary blockages are at risk for heart attacks and strokes. Even individuals with normal levels of low-density lipoprotein (LDL), known as the so-called “bad” cholesterol, but still at risk, seem to be identified.